You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDK9i

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Learn About Use and Effects of CDK4/6 Inhibitors in Canadian

Active, not recruiting
  • Breast Cancer
    • Kirkland, Quebec, Canada
      Pfizer Canada
    Mar 5, 2023

    Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

    Recruiting
    • Locally Advanced Breast Cancer
    • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
    • Jinan, Shandong, China
      Breast Cancer Center, Shandong Cancer Hospital and Institute
    Apr 11, 2023

    Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

    Recruiting
    • Breast Cancer
    • Endocrine Therapy and a CDK 4/6 inhibitor
    • Baltimore, Maryland
      Johns Hopkins University
    Jul 18, 2022

    Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

    Recruiting
    • Neurofibromatosis 1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 30, 2023

    Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Tianjin, China
      Tianjin Cancer Hospital
    Mar 28, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • chidamide combined with fulvestrant
    • (no location specified)
    Mar 28, 2023

    Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with

    Recruiting
    • Inhibition of Autophagy Synergizes Anti-tumor Effect
    • 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
    • RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Jul 19, 2023

    Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

    Not yet recruiting
    • Breast Cancer
    • Marseille, France
      Institut Paoli Calmettes
    Aug 9, 2023

    Cutaneous T-cell Lymphoma (CTCL) Trial in United Kingdom (CDK-003)

    Recruiting
    • Cutaneous T-cell Lymphoma (CTCL)
    • CDK-003
    • Birmingham, United Kingdom
    • +3 more
    Apr 22, 2022

    Advanced Solid Tumor Trial in United Kingdom, United States (CDK-002)

    Active, not recruiting
    • Advanced Solid Tumor
    • CDK-002
    • Scottsdale, Arizona
    • +7 more
    Sep 27, 2022

    Leukemia, Myelodysplastic Syndrome(MDS) Trial in Duarte, Houston (fadraciclib)

    Recruiting
    • Leukemia
    • Myelodysplastic Syndrome(MDS)
    • Duarte, California
    • +1 more
    Apr 1, 2022

    Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

    Recruiting
    • Lung Cancer Squamous Cell
    • +3 more
    • Boston, Massachusetts
    • +2 more
    Jan 9, 2023

    Solid Tumor, Adult, Lymphoma Trial in Korea, Republic of, Spain, United States (Fadraciclib)

    Recruiting
    • Solid Tumor, Adult
    • Lymphoma
    • Duarte, California
    • +3 more
    Apr 1, 2022

    Metastatic Breast Cancer, Recurrent Ovarian Carcinoma Trial in Salt Lake City, Fairfax (Ribociclib, Belinostat)

    Recruiting
    • Metastatic Breast Cancer
    • Recurrent Ovarian Carcinoma
    • Salt Lake City, Utah
    • +1 more
    May 3, 2022

    Advanced Solid Tumor Trial (9MW2921)

    Not yet recruiting
    • Advanced Solid Tumor
    • (no location specified)
    Aug 14, 2023

    Lymphoma, Solid Tumor Trial in Buffalo (Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study)

    Terminated
    • Lymphoma
    • Solid Neoplasm
    • Gemcitabine Hydrochloride
    • +3 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jul 20, 2022

    Breast Cancer Trial in Shanghai (SCR-6852, Palbociclib)

    Recruiting
    • Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    May 18, 2022

    Head Neck Cancer, Locally Advanced Trial in Bangkok (Palbociclib, Cetuximab, Intensity Modulated Radiation Therapy)

    Active, not recruiting
    • Head and Neck Cancer
    • Locally Advanced
    • Bangkok, Thailand
      Faculty of Medicine, Ramathibodi Hospital
    Sep 19, 2022

    Lung Cancer Trial in Boston (Binimetinib, Palbociclib)

    Recruiting
    • Lung Cancer
    • Boston, Massachusetts
    • +1 more
    Jan 18, 2022

    Digestive System Tumors Trial in Zhengzhou (a CDK4 / 6 inhibitor and a MEK inhibitor)

    Recruiting
    • Digestive System Tumors
    • a CDK4 / 6 inhibitor and a MEK inhibitor
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Aug 20, 2021

    Soft-tissue Sarcoma, Osteosarcoma, Chordoma Trial in Spain (Palbociclib)

    Recruiting
    • Soft-tissue Sarcoma
    • +2 more
    • Barcelona, Spain
    • +18 more
    May 30, 2022

    Prostate Cancer Trial in Canada (Palbociclib)

    Active, not recruiting
    • Prostate Cancer
    • Halifax, Nova Scotia, Canada
    • +6 more
    Jan 28, 2022

    Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Washington, District of Columbia
      Lombardi Comprehensive Cancer Center
    Jan 17, 2022